Molnupiravir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Molnupiravir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
50
Registered trials
32
Result records
11
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Molnupiravir can convert its Small molecule drug profile and RdRp biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Molnupiravir (query alias: molnupiravir) |
|---|---|
| Modality / target | Small molecule drug; RdRp; RdRp inhibitors, Virus replication inhibitors |
| Highest global status | Approved |
| Originator | Emory University |
| Active developers | MSD KK (Tokyo), Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp. |
The MCP disease footprint includes COVID-19, Encephalomyelitis, Venezuelan Equine. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06667700 | Phase 3 | Recruiting | 3082 | Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization, All-cause Mortality, or Covid-19-related Medically-attended Visit (MAV) |
| NCT06615869 | Phase 1 | Completed | 64 | Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of N-Hydroxycitidine (NHC) in plasma: Treatment A versus Treatment B |
| NCT06816030 | Phase 1 | Completed | 16 | The Maximum Observed Plasma Concentration (Cmax) After Single Oral Dose of MK-4482 in Period 1 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial
Phase 3; n=1810; evaluation: Negative. Reported fields: Anti-SARS-CoV-2 antibodies = 37.1 % ; Anti-SARS-CoV-2 antibodies = 33.7 %
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Phase 3; n=not disclosed; evaluation: Negative. Reported fields: 28-day mortality = 19 % ( 19%); 28-day mortality = 17 % ( 17%); 28-day mortality = 17 % ( 17%)
A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Symptom resolution = 8.5 day ; Symptom resolution = 6.0 day
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Molnupiravir addresses COVID-19, Encephalomyelitis, Venezuelan Equine. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-11-07 | 默沙东与国药控股Ridgeback就抗新冠病毒口服药物莫诺拉韦在华经销达成协议 | Approved | Financial terms not disclosed |
| 2022-09-28 | 默沙东与国药集团联合宣布就抗新冠病毒口服药物在华达成合作框架协议 | Approved | Financial terms not disclosed |
| 2022-02-07 | University of Pennsylvania and University of Maryland collaborate on a study of combining remdesivir or molnupiravir with brequinar for COVID-19. | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
